• Technical Use of Angiotensin I/II (1-5) in RAS Research Work

  2026-05-03

  Angiotensin I/II (1-5) provides a defined Asp-Arg-Val-Tyr-Ile peptide fragment for modeling blood pressure regulation and aldosterone signaling in cardiovascular and renal research. It is unsuitable for applications outside the renin-angiotensin system or workflows not requiring explicit peptide hormone vasoconstriction modeling.

• Latrunculin B in Translational Research: Mechanism, Strategy

  2026-05-02

  Explore how Latrunculin B (APExBIO, SKU C5804) advances cytoskeletal research by precisely inhibiting actin filament assembly. This article examines its mechanistic foundations, protocol parameters, competitive positioning, and translational impact—bridging rigorous evidence with actionable guidance and a forward-looking outlook for biomedical innovators.

• Effects of Antiarrhythmics on SK Channels in AF: Insights &

  2026-05-02

  This study systematically evaluated whether clinically recommended antiarrhythmic drugs, including dronedarone, modulate small conductance calcium-activated potassium (KCa2.X/SK) channels in human atrial models. The findings show that most current agents, such as dronedarone, have negligible direct action on SK channels at therapeutically relevant concentrations, refining our understanding of atrial fibrillation (AF) pharmacology and guiding future target selection.

• Glycogen Colorimetric Assay II: Transforming Metabolic Resea

  2026-05-01

  Unpack how the Glycogen Colorimetric Assay Kit II empowers translational scientists to interrogate muscle and liver glycogen regulation in preclinical models, with special focus on endurance adaptation, circadian effects, and high-throughput workflows. Grounded in recent primary evidence, this piece highlights APExBIO’s competitive differentiation and provides actionable protocol guidance for metabolic innovation.

• CHK1 Inhibition and Hormone Receptor Status in Breast Cancer

  2026-04-30

  This study delineates how the therapeutic efficacy of CHK1 inhibition in breast cancer is fundamentally modulated by estrogen and progesterone receptor status. By integrating transcriptome analyses and functional assays, the research details context-specific mechanisms that inform the strategic application of CHK1 inhibitors in targeted oncology.

• Pharmacokinetics of Corydalis saxicola Alkaloids in MASH Mod

  2026-04-30

  This study systematically investigates the pharmacokinetic variability and tissue distribution of key alkaloids from Corydalis saxicola Bunting in a murine model of metabolic dysfunction-associated steatohepatitis (MASH). The findings highlight how disease pathology and dosing regimen modulate systemic exposure, hepatic accumulation, and transporter/enzyme expression, providing an evidence base for rationalizing dosing strategies in MASH therapy.

• IWR-1-endo: Mechanistic Dissection and Advanced Protocols fo

  2026-04-29

  Explore the in-depth mechanism and advanced research applications of IWR-1-endo, a potent Wnt signaling inhibitor. This article uniquely connects molecular insight to practical assay decisions, advancing beyond standard reviews.

• VEGFC–VEGFR-3 Axis Disruption Mitigates NASH-Driven Hepatic

  2026-04-29

  This study uncovers the central role of the hepatocyte-derived VEGFC–VEGFR-3 axis in driving hepatic fibrosis in NASH, demonstrating that its inhibition—via genetic or pharmacological strategies—attenuates inflammation and fibrotic progression. These findings position VEGFR-3 inhibition as a mechanistically validated approach for dissecting anti-fibrotic pathways in metabolic liver disease.

• ALDOB K87 Lactylation Drives Mitochondrial Fission in PH

  2026-04-28

  This study identifies ALDOB K87 lactylation as a pivotal driver of mitochondrial fission and metabolic reprogramming in pulmonary hypertension (PH). Through proteomic profiling and mechanistic validation, the authors link lactate metabolism to smooth muscle cell proliferation and vascular remodeling, providing new targets for PH research.

• Cyclosporin A: Optimizing Immunosuppression and Mitochondria

  2026-04-28

  Cyclosporin A is more than an immunosuppressive cyclic undecapeptide—it is a precision tool for dissecting T-cell activation, mitochondrial permeability, and signaling. This article delivers actionable workflows, troubleshooting, and key innovations for advanced research, linking bench protocols with translational impact.

• Amyloid β-Peptide (1-42): Optimizing Neurotoxicity and Micro

  2026-04-27

  Amyloid β-Peptide (1-42) (Aβ42) is pivotal for modeling Alzheimer's disease mechanisms, from neuronal toxicity to microglial activation. This article delivers actionable, experiment-ready workflows and troubleshooting strategies, translating recent reference breakthroughs into reproducible, high-impact assays.

• AZD0156: Precision ATM Kinase Inhibitor for Cancer Research

  2026-04-27

  AZD0156 offers unmatched potency and selectivity as an ATM kinase inhibitor, empowering researchers to dissect DNA repair and metabolic adaptation in advanced cancer models. Explore evidence-backed workflows, synergistic applications, and troubleshooting strategies that maximize the impact of this tool in DNA damage response and therapeutic discovery.

• Brefeldin A (BFA): Reliable ER Stress and Apoptosis Inductio

  2026-04-26

  This article presents scenario-driven, evidence-based guidance for deploying Brefeldin A (SKU B1400) as an ER stress inducer and apoptosis modulator in cancer and cell biology assays. Drawing from recent literature and product specifications, it addresses real-world optimization challenges and highlights the reproducibility and workflow advantages of Brefeldin A from APExBIO.

• Nutlin-3a in Precision Oncology: Unraveling MDM2 Inhibition

  2026-04-25

  Explore how Nutlin-3a, a leading MDM2 inhibitor, enables cutting-edge research into p53 pathway activation, apoptosis, and advanced cancer biology. This article delivers unique assay insights and strategic context distinct from prior Nutlin-3a coverage.

• ATRX Deficiency Sensitizes Glioma Cells to RTK and PDGFR Inh

  2026-04-24

  This study demonstrates that high-grade glioma cells lacking ATRX are significantly more sensitive to multi-targeted receptor tyrosine kinase (RTK) and platelet-derived growth factor receptor (PDGFR) inhibitors. These findings suggest ATRX status should be considered in clinical trial stratification and design for targeted therapies in glioma.

16231 records 1/1083 page Next 12345 下5页 Last page